NHS National Framework Agreement for the Supply of products for the management of Hereditary Angioedema
Estimated value
—
Awarded value
—
Suppliers
14
Lots
7
Published
19 Jul 2022
Description
National Framework Agreement for the supply of products for the management of Hereditary Angioedema. The framework will commence on 1 July 2022 for a period of 18 months with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 30 months. <br/>Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the invitation to offer documents for a list of the purchasing points.
Scope
- Reference
- CM/PHS/19/5583
- Commercial tool
- Standalone contract
- Main category
- goods
- CPV classifications
- 33600000
- Contract locations
- UK
Award criteria
Criteria the buyer will use to evaluate bids.
| Name | Description | Type | Weighting |
|---|---|---|---|
| Security of Supply | 20% | quality | — |
| Ease of Use | 10% | quality | — |
| — | 70% | price | — |
Submission & procedure
- Procedure
- Open procedure
Award details· 14 awards
Awarded supplier(s), contract period and value as published in the award notice.
Awarded value
—
Award date
—
Contract start
—
Contract end
—
Lots · 7 total
Divisions of the contract. Each lot can be awarded separately.
| Lot | Title | Est. value | Status |
|---|---|---|---|
| 1 | Lot 1 – C1 Esterase – Recombinant IV (acute treatment) | — | cancelled |
| 3 | Lot 3 - C1 Esterase – Plasma derived IV (prophylaxis treatment) | — | cancelled |
| 6 | Lot 6 - Lanadelumab | — | cancelled |
| 7 | Lot 7 - Berotralstat | — | cancelled |
| 2 | Lot 2 - C1 Esterase – Plasma derived IV (acute treatment) | — | cancelled |